Neurology

 

Neurology

Advancing
CNS Biomarker Detection

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.

Simoa assays can detect neurological biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS)  and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.

Latest News

09.21
In this month’s JAMA Neurology, two papers examine whether tau circulating in plasma could offer a blood-based biomarker for brain disorders.
09.07
Discussion will be led by Dr. Edward Wild and Lauren Byrne from the UCL Institute of Neurology, with introductory remarks from Kevin Hrusovsky, Executive Chairman and CEO, Quanterix